Other
Lessee Operating Lease Liability Payments Due
Neurocrine Biosciences Lessee Operating Lease Liability Payments Due decreased by 4.7% to $590.20M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 8.6%, from $645.90M to $590.20M. This is a positive signal — lower values indicate better performance for this metric.
Analysis
StatementBalance Sheet Statement
SectionOther
CategoryRisk
SignalLower is better
VolatilityStable
First reportedQ2 2020
Last reportedQ1 2026May 5, 2026
How to read this metric
An increase indicates higher long-term fixed operational costs, while a decrease suggests a reduction in lease commitments.
Detailed definition
This represents the total undiscounted future cash payments required under operating lease agreements. It reflects the f...
Peer comparison
Standardized across all companies reporting under ASC 842, allowing for direct comparison of fixed operational debt-like obligations.
Metric ID:
other_lessee_operating_lease_liability_payments_dueHistorical Data
15 periods
| Q2 '21 | Q3 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $159.30M | $155.70M | $150.30M | $146.00M | $141.70M | $132.90M | $130.70M | $126.10M | $377.40M | $381.00M | $372.10M | $645.90M | $636.50M | $619.50M | $590.20M |
| QoQ Change | — | -2.3% | -3.5% | -2.9% | -2.9% | -6.2% | -1.7% | -3.5% | +199.3% | +1.0% | -2.3% | +73.6% | -1.5% | -2.7% | -4.7% |
| YoY Change | — | — | — | -8.3% | -9.0% | -11.6% | -10.5% | -11.0% | +184.0% | +191.5% | +195.1% | +71.1% | +67.1% | +66.5% | -8.6% |
Range$126.10M – $645.90M
CAGR+45.4%
Avg YoY Growth+59.7%
Median YoY Growth+29.1%
Current Streak3 quarters decline
Lessee Operating Lease Liability Payments Due at Other Companies
Frequently Asked Questions
- What is Neurocrine Biosciences's lessee operating lease liability payments due?
- Neurocrine Biosciences (NBIX) reported lessee operating lease liability payments due of $590.20M in Q1 2026.
- How has Neurocrine Biosciences's lessee operating lease liability payments due changed year-over-year?
- Neurocrine Biosciences's lessee operating lease liability payments due decreased by 8.6% year-over-year, from $645.90M to $590.20M.
- What does lessee operating lease liability payments due mean?
- The total amount of future cash payments the company is contractually obligated to pay for operating leases.